[PDF][PDF] Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy …
J Clin Oncol, 2013•academia.edu
Purpose The antiepidermal growth factor receptor monoclonal antibody cetuximab has
improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS
colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has
shown encouraging early clinical activity.
improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS
colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has
shown encouraging early clinical activity.
Purpose
The antiepidermal growth factor receptor monoclonal antibody cetuximab has improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has shown encouraging early clinical activity.
academia.edu
